Welcome to our dedicated page for Petvivo Holdings news (Ticker: PETVW), a resource for investors and traders seeking the latest updates and insights on Petvivo Holdings stock.
PetVivo Holdings, Inc. (warrants trading as PETVW alongside common stock PETV on OTCQX) generates a steady flow of news around its role as an emerging biomedical device company in the companion animal and equine markets. Company releases highlight developments in its veterinary medical devices and therapeutics, AI-powered platforms, distribution partnerships and corporate governance, providing context for investors and veterinary professionals following the PETVW warrants.
Recent news has focused on SPRYNG® with OsteoCushion® technology and PrecisePRP®, PetVivo’s lead products for managing joint-related conditions and musculoskeletal restoration in cats, dogs and horses. Articles describe clinical adoption, distributor expansion, continuing education initiatives for veterinarians and collaborations with equine-focused partners that integrate these products into care protocols.
Another major news theme is the company’s move into artificial intelligence through PetVivo AI, Inc. and the PetVivo.ai platform. Press releases detail an exclusive 10-year licensing agreement for the Agentic Pet AI framework, beta testing results, and the launch of a two-sided ecosystem that uses specialized AI agents to reduce veterinary client acquisition costs and connect practices with engaged pet parents. Additional coverage discusses technical validation of the framework via a published whitepaper and the release of a video explainer for PetVivo.ai.
News items also cover earnings announcements, conference calls and investor presentations, as well as board changes such as the appointment of an independent director. For anyone tracking PETVW, this news page offers a centralized view of PetVivo’s operational updates, product milestones, AI initiatives and strategic partnerships. Investors and observers can review these articles to understand how the company’s veterinary devices, regenerative products and AI platforms are being positioned in the animal health market.
PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) has announced a distribution agreement with VetCove, Inc. to market its therapeutic product, SPRYNG™ with OsteoCushion™ Technology. VetCove, utilized by over 13,000 veterinary hospitals, will enable easier access for veterinarians to order SPRYNG for pets suffering from osteoarthritis. This innovative device, comprised of micronized hydrogel matrices, aims to support joint health and alleviates lameness. PetVivo also holds a diverse pipeline of products, enhancing its position in the veterinary market.
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO John Lai will discuss the company's business overview on January 10 at 12:00 PM EST. PetVivo focuses on innovative medical devices for pets, including its lead product, SPRYNG, which targets joint issues in animals. The company holds 21 patents and plans for expanded commercial sale of SPRYNG in Q4 2022. For more details, visit PetVivo's official website.
PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announced a successful showcase of its product, Spryng™, at the American Association of Equine Practitioners (AAEP) conference from December 4-8, 2021. Spryng utilizes OsteoCushion™ Technology for treating lameness and joint issues like osteoarthritis. The company received positive feedback from veterinarians, indicating strong interest in adopting Spryng. PetVivo is offering a promotional deal through December 31, 2021, providing an extra syringe for every five purchased. The company plans expanded sales of Spryng in Q4 2021.
PetVivo Holdings, Inc. (NASDAQ: PETV) will participate in the American Association Equine Practitioners (AAEP) conference from December 4-8, 2021, in Nashville, TN. The company aims to showcase its lead product, SPRYNG™, featuring OsteoCushion™ Technology, designed to treat lameness and joint issues, including osteoarthritis, in pets. The AAEP conference is expected to draw over 5,000 industry professionals, presenting opportunities for networking and business development. The company plans to expand commercial sales of SPRYNG in Q4 2021.
PetVivo Holdings announces a comprehensive digital media campaign to promote its product Spryng™, targeting improvements in animal lameness. The campaign includes 40 interviews and 600 T.V. commercials over the next year on major networks like Newsmax and Bloomberg. Additionally, 2,400 digital billboard ads will be displayed daily in Manhattan. Spryng™, which aids osteoarthritis in pets, is set for expanded sales this quarter. PetVivo aims to leverage veterinary opportunities similar to human therapies, supported by a robust patent portfolio.
PetVivo Holdings raised approximately $11.25 million through an Initial Public Offering, rebranding Kush™ as Spryng™ and initiating sales. In Q2 2022, revenue reached $4,977, up from $4,790 in Q2 2021. The company reported a net loss of $1,105,474, improved from $1,348,002 in the same period last year. For the six months ended September 30, 2021, revenue was $9,122. The company aims to utilize offering proceeds to enhance sales and marketing efforts and has made key management hires.
PetVivo Holdings, Inc. (Nasdaq: PETV, PETVW) raised approximately $11.25 million through an Initial Public Offering, rebranding Kush™ to Spryng™. As of September 30, 2021, revenues increased to $4,977 for Q2 2021 from $4,790 in Q2 2020. Net loss decreased to ($1,105,474) compared to ($1,348,002) year-over-year. Significant investments in sales, marketing, and research were made to support the launch of Spryng™. Key management hires were also announced.
PetVivo Holdings, Inc. will release its financial results for Q2 FY 2022 on November 15, 2021, post-market. A conference call is scheduled for 4:00 p.m. CT to discuss these results. The call will be available via webcast on their Investor Relations website. PetVivo focuses on innovative medical devices for animals, leveraging human therapies to expedite market entry. They have a pipeline of 17 products and 21 patents, with their lead product, SPRYNG™, aimed at treating osteoarthritis in dogs and horses, set for expanded sales this quarter.
PetVivo Holdings closed its public offering of 2,500,000 units at $4.50 each, raising approximately $11.25 million. Each unit comprises one common stock share and a warrant to purchase one share at $5.625, exercisable immediately for five years. The offering, which included an over-allotment option of 375,000 warrants exercised by the underwriter, supports marketing, R&D, and debt repayment. The stock began trading on Nasdaq under the symbols PETV and PETVW on August 11, 2021.
PetVivo Holdings, Inc. (Nasdaq: PETV, PETVW) has announced a public offering of 2,500,000 units at $4.50 each, raising approximately $11.25 million. Each unit consists of one share of common stock and one warrant, which can be exercised at $5.625 over five years. The offering is expected to close on August 13, 2021, with proceeds used for marketing, debt repayment, R&D, and working capital. ThinkEquity is the sole book-running manager. The common stock and warrants are set to begin trading on August 11, 2021.